Therapeutics Enter Oncology Articles & Analysis
48 news found
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need. The Menarini Group (“Menarini”), a ...
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement. This agreement covers the execution of a Phase 2 clinical trial to evaluate the novel combination of ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
Regor Therapeutics, a clinical-stage biotech company, announced today the Investigational New Drug (IND) Application for RGT-264 phosphate tablet, a small molecular selective hematopoietic progenitor kinase (HPK1) inhibitor has been approved by the National Medical Products Administration (NMPA) of China. RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ambition to bring immunotherapies to the clinic, ...
Results from the primary analysis of the SUNLIGHT trial to be presented at an upcoming scientific conference Paris - September 12, 2022– Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. ...
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...
Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer ...
Plan ensures shareholders are protected and treated equitably Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional ...
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. (NASDAQ: HOOK, ...
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of ...
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). ...
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France). The meeting was chaired by Hedi Ben Brahim, CEO, to approve the Company’s financial statements for ...
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New ...
Regor Therapeutics Group announced that the investigational new drug (IND) application of RGT-419B capsule, a CDK2/4/6 small molecule inhibitor, had been approved by the National Medical Products Administration (NMPA) of China. A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) ...
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of ...
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic ...